Silvina Gallo
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study.
Journal: The Lancet. Neurology
Published: July 22, 2025
Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
Journal: Diabetes, obesity & metabolism
Published: December 16, 2020
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Journal: The New England journal of medicine
Published: September 23, 2020
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: April 29, 2020
The effects of ertugliflozin on β-cell function: Pooled analysis from four phase 3 randomized controlled studies.
Journal: Diabetes, obesity & metabolism
Published: March 12, 2020
Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus.
Journal: Obesity (Silver Spring, Md.)
Published: November 05, 2019
Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies.
Journal: Diabetes & vascular disease research
Published: May 14, 2019
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
Journal: Cardiovascular diabetology
Published: January 22, 2019
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Journal: Diabetes, obesity & metabolism
Published: October 16, 2018
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
Journal: American heart journal
Published: July 07, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026